Beckman Coulter, Inc.
250 S Kraemer Blvd
Tel: (714) 993-5321
295 articles with Beckman Coulter, Inc.
Beckman Coulter's Early Sepsis Indicator Receives 510(k) Clearance from the U.S. Food and Drug Administration
New hematologic biomarker has the potential to revolutionize clinicians' approach to sepsis triage and diagnosis
With just 17 microliters of blood, the DxH 520 enables low-volume laboratories to deliver 5-part differential test results in 60 seconds or less
Beckman Coulter's HbA1c Advanced Assay Provides Physicians with Greater Accuracy when Diagnosing Patients with Diabetes
New assay achieves CE Mark Certification and U.S. FDA 501(k) Clearance
Cloud-based solution streamlines labor-intensive inventory management tasks to improve resource management
Ongoing Customer-Driven Site Enhancements Designed to Improve User Experience
Beckman Coulter Diagnostics Joins Forces with Johns Hopkins Medicine in Healthcare Innovation Initiative
Beckman Coulter Diagnostics, a global leader in the clinical diagnostics industry, is embarking on an innovation collaboration with Johns Hopkins Medicine to explore co-innovation initiatives with the goal of developing and commercializing novel solutions that address challenges in healthcare.
BioBright and Beckman Coulter Announce a Strategic Partnership to Bring Enhanced Technical Support Capabilities to Instruments
BioBright and Beckman Coulter announce a strategic partnership to bring enhanced technical support capabilities to instruments.
REMISOL Advance* v1.10 software helps to ensure continuous operations and efficient delivery of critical results by giving mid- to high-volume laboratories real-time, actionable analytics at-a-glance
Beckman Coulter, a global leader in the clinical diagnostics industry, announced today that it is a gold sponsor of the 2nd World Sepsis Congress, a free-of-charge online conference, hosted by the Global Sepsis Alliance, that will be held Sept. 5 and 6, 2018.
System enhancements provide laboratories with gold-standard accuracy to optimize patient care and reduce the risk of emerging antimicrobial resistance
Beckman Coulter and U.S. ARKRAY, Inc., Announce Partnership and Launch of the iQ Workcell to Deliver Scalable, Harmonized Solutions in the United States
Industry-leading iQ200 urine microscopy and AUTION MAX™ AX-4030 urine chemistry technology offer scalable, harmonized solution to meet customer needs
Recognizes 'care, dedication and commitment' of ordinary people
Published findings show initial testing for three specific biomarkers may provide superior results over standard screening methods
System helps laboratories deliver fast, accurate results through near native-state cellular characterization, precise flagging and a 93% first-pass throughput
The new Access Sensitive Estradiol assay rounds out the comprehensive reproductive menu for the Access immunoassay systems and provides better operational efficiency while delivering quality results
Beckman Coulter announced FDA clearance of its automated Access AMH immunoassay for IVD use in the U.S.
To further these goals, Beckman Coulter plans in the future to sell directly to its customers a natriuretic peptide assay for its Access Family of Immunoassay Systems.
Beckman Coulter's Recently Published Study Reports a Significant Reduction in Biopsy Procedures Performed When Prostate Health Index (Phi) Testing is Used by Physicians in Routine Clinical Practice
A study published in Prostate Cancer and Prostatic Diseases demonstrated that physicians elected to perform fewer biopsies when phi testing was included in their overall, routine, clinical assessment.
Quidel Announces Early Termination Of The Hart-Scott-Rodino Waiting Period For Its Pending Acquisition Of Alere’s Triage B-Type Naturietic Peptide (BNP) Assay Business Run On Beckman Coulter Analyzers
Quidel Announces Revised Agreement For Its Pending Acquisition Of Alere’s B-Type Naturietic Peptide (BNP) Assay Business Run On Beckman Coulter Analyzers